Continued Ventilation During Cardiopulmonary Bypass
Cardiopulmonary bypass (CPB) is well known to induce a strong anti-inflammatory response. The investigators examined whether continued mechanical ventilation during CPB alters systemic immune activation.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
|Official Title:||Continued Mechanical Ventilation During CABG Operation Attenuates Systemic Immune Modulation|
- Alteration of soluble ST2 concentration in serum [ Time Frame: Preoperative, postoperative, day 1, day 2, day 3, day 4, day 5 after surgery ] [ Designated as safety issue: No ]Concentration of soluble ST2 will be assessed in the serum of patient´s preoperativem, postoperative and the following five consecutive days after surgery.
|Study Start Date:||April 2009|
|Study Completion Date:||August 2010|
|Primary Completion Date:||August 2010 (Final data collection date for primary outcome measure)|
Experimental: Ventilation Group
Volume controlled ventilation was done during the whole surgery.
Other: Lung Ventilation
In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
No Intervention: Non-ventilation Group
In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
Other: Non-ventilated Group
. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
Cardiopulmonary bypass is well known to induce a strong anti-inflammatory response. Studies had been shown that the contact of blood components with artificial surfaces, the surgical trauma, endotoxemia and a reperfusion injury are in part responsible for the seen immunological affect after surgery. The purpose of this study is to test the effect of continued mechanical ventilation during surgery on a blood marker called soluble ST2 in patients sera. Soluble ST2 acts as a decoy receptor of IL-33 and has anti-inflammatory effects. Elevated soluble ST2 concentrations are reported in patients with acute myocardial infarction, sepsis, congestive heart failure and elevates soluble ST2 levels are associated with adverse outcome.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01627756
|Medical University of Debrecen|
|Debrecen, Hungary, Nagyerdei krt. 98|
|Principal Investigator:||Hendrik Jan Ankersmit, MD||Medical University of Vienna|